{"id":"alpiropride","rwe":[],"tags":[{"label":"alpiropride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["alpiropride"],"offLabel":[],"synonyms":["alpiropride"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"alpiropride","explanation":"Imagine your brain is a city with many different streets and buildings. Dopamine is like a messenger that helps different parts of the city communicate with each other. Alpiropride is like a key that helps this messenger work more effectively, which can help treat certain conditions.","oneSentence":"Alpiropride works by binding to dopamine receptors in the brain.","technicalDetail":"Alpiropride is a dopamine D2 receptor agonist, which means it binds to and activates dopamine receptors in the brain, mimicking the action of dopamine and potentially treating conditions related to dopamine deficiency or dysfunction."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/135","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALPIROPRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:38:14.255483","biosimilars":[],"competitors":[],"genericName":"alpiropride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1768UW0XS1","INN_ID":"5290","UMLSCUI":"C2346723","ChEMBL_ID":"CHEMBL2104024","PUBCHEM_CID":"71253"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.8 hours","clearance":"5.47 mL/min/kg","volumeOfDistribution":"2.3 L/kg"},"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ALPIROPRIDE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpiropride is a small molecule drug in the alpiropride class, originally developed by an unknown entity and currently owned by an unknown entity. Its target and approved indications are unknown, and it has not been approved by the FDA. Alpiropride has a half-life of 4.8 hours, but its bioavailability and commercial status are unknown. Further research is needed to determine its safety and efficacy. As a result, it is not commercially available.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}